Research symposia focus on new combinations and medication formulations for both obesity and type 2 diabetes, as well as new ...

(Reuters) -Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer ...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

Eli Lilly announced that the highest doses of tirzepatide (Zepbound) -- 12.5 mg and 15 mg -- will soon be available in single ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

Obesity in India is a chronic disease, not a personal failure, requiring empathy, science-based treatment, and public health strategies.

The Mark Cuban Cost Plus Drug Company has entered into a new partnership with the aim of making obesity medications ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects.

Researchers from George Washington University have uncovered promising evidence in an animal study that shows setmelanotide, ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...